These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 20004570

  • 1. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG, Sannigrahi M, Bogen S, Pinto P, Chen KX, Prongay A, Tong X, Cheng KC, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):567-70. PubMed ID: 20004570
    [Abstract] [Full Text] [Related]

  • 2. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
    Nair LG, Bogen S, Ruan S, Pan W, Pike R, Tong X, Cheng KC, Guo Z, Doll RJ, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1689-92. PubMed ID: 20149655
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
    Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B, Liu R, Cheng KC, Guo Z, Tong X, Saksena AK, Girijavallabhan V, Njoroge FG.
    J Med Chem; 2009 Jun 25; 52(12):3679-88. PubMed ID: 19456105
    [Abstract] [Full Text] [Related]

  • 7. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL, Chen KX, Pike RE, Sannigrahi M, Soares J, Venkatraman S, Vibulbhan B, Saksena AK, Girijavallabhan V, Tong X, Cheng KC, Njoroge FG.
    J Med Chem; 2009 May 14; 52(9):2806-17. PubMed ID: 19371095
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
    Bilodeau F, Bailey MD, Bhardwaj PK, Bordeleau J, Forgione P, Garneau M, Ghiro E, Gorys V, Halmos T, Jolicoeur ES, Leblanc M, Lemke CT, Naud J, O'Meara J, White PW, Llinàs-Brunet M.
    Bioorg Med Chem Lett; 2013 Jul 15; 23(14):4267-71. PubMed ID: 23735741
    [Abstract] [Full Text] [Related]

  • 10. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
    Bogen SL, Arasappan A, Velazquez F, Blackman M, Huelgas R, Pan W, Siegel E, Nair LG, Venkatraman S, Guo Z, Doll R, Shih NY, Njoroge FG.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1854-65. PubMed ID: 20149666
    [Abstract] [Full Text] [Related]

  • 11. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 01; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 12. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 13. P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors.
    Sun DX, Liu L, Heinz B, Kolykhalov A, Lamar J, Johnson RB, Wang QM, Yip Y, Chen SH.
    Bioorg Med Chem Lett; 2004 Aug 16; 14(16):4333-8. PubMed ID: 15261297
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX, Vibulbhan B, Yang W, Nair LG, Tong X, Cheng KC, Njoroge FG.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1105-9. PubMed ID: 19168351
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM, Barnes MC, Dowle MD, Hind SL, Johnson MR, Jones PS, Mills G, Patikis A, Pateman TJ, Redfern TJ, Robinson JE, Slater MJ, Trivedi N.
    Org Lett; 2003 Nov 27; 5(24):4631-4. PubMed ID: 14627401
    [Abstract] [Full Text] [Related]

  • 18. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
    Chen KX, Nair L, Vibulbhan B, Yang W, Arasappan A, Bogen SL, Venkatraman S, Bennett F, Pan W, Blackman ML, Padilla AI, Prongay A, Cheng KC, Tong X, Shih NY, Njoroge FG.
    J Med Chem; 2009 Mar 12; 52(5):1370-9. PubMed ID: 19196021
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.